litlas
Log inCreate account

David B. Miklos

Active 1999–2025

Also published as
David B Miklos
130
Papers
29,259
Citations
63
h-index
122
i10-index

Citations

Citations per year for David B. Miklos1990: 1 citations1992: 1 citations1999: 7 citations2000: 28 citations2001: 30 citations2002: 25 citations2003: 23 citations2004: 26 citations2005: 23 citations2006: 52 citations2007: 30 citations2008: 34 citations2009: 38 citations2010: 46 citations2011: 54 citations2012: 108 citations2013: 116 citations2014: 113 citations2015: 97 citations2016: 88 citations2017: 94 citations2018: 201 citations2019: 715 citations2020: 1,134 citations2021: 1,566 citations2022: 1,677 citations2023: 1,413 citations2024: 2,316 citations2025: 1,230 citations2026: 30 citations1991: no citations, so this year is not shown1993–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,610 citing papers, 32.6% of this breakdownChina: 1,099 citing papers, 9.9% of this breakdownGermany: 765 citing papers, 6.9% of this breakdownUnited Kingdom: 579 citing papers, 5.2% of this breakdownFrance: 505 citing papers, 4.6% of this breakdownItaly: 475 citing papers, 4.3% of this breakdownSpain: 390 citing papers, 3.5% of this breakdownCanada: 353 citing papers, 3.2% of this breakdownAustralia: 305 citing papers, 2.7% of this breakdownSwitzerland: 264 citing papers, 2.4% of this breakdownNetherlands: 258 citing papers, 2.3% of this breakdownJapan: 206 citing papers, 1.9% of this breakdown
0%32.6%Other 20.5%

Institutions

Fields

  • Medicine80.7%
  • Biochemistry, Genetics and Molecular Biology8.1%
  • Immunology and Microbiology7%
  • Environmental Science1.7%
  • Engineering0.6%
  • Neuroscience0.5%
  • Other1.4%

Topics

  • CAR-T cell therapy research20.4%
  • Immune Cell Function and Interaction5.9%
  • Lymphoma Diagnosis and Treatment5.4%
  • Virus-based gene therapy research4.9%
  • Nanowire Synthesis and Applications3.4%
  • T-cell and B-cell Immunology2.9%
  • Other57.1%

Coauthors

All papers

Open in search
  1. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Authors: Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick J. Stiff, Jonathan W. Friedberg, Ian W. Flinn, André Goy, Brian T. Hill, Mitchell R. Smith, Abhinav Deol, Umar Farooq, Peter A. McSweeney, Javier Muñoz, Irit Avivi, Januario E. Castro, Jason R. Westin, Julio C. Chávez, Armin Ghobadi, Krishna V. Komanduri, Ronald Levy, Eric D. Jacobsen, Thomas E. Witzig, Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek, William Y. Go - New England Journal of Medicine 2017 cited by 5,915

  2. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

    Authors: Frederick L. Locke, David B. Miklos, Caron A. Jacobson, Miguel‐Angel Perales, Marie José Kersten, Olalekan O. Oluwole, Armin Ghobadi, Aaron P. Rapoport, Joseph P. McGuirk, John M. Pagel, Javier Muñoz, Umar Farooq, Tom van Meerten, Patrick M. Reagan, Anna Sureda, Ian W. Flinn, Peter Vandenberghe, Kevin Song, Michael Dickinson, Monique C. Minnema, Peter A. Riedell, Lori A. Leslie, Sridhar Chaganti, Yin Yang, Simone Filosto, Jina Shah, Marco Schupp, Christina To, Paul Cheng, Leo I. Gordon, Jason R. Westin - New England Journal of Medicine 2021 cited by 1,520

  3. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

    Authors: Michael Wang, Javier Muñoz, André Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Nöel Milpied, Henry C. Fung, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Lianqing Zheng, John M. Rossi, Rajul K. Jain, Arati V. Rao, Patrick M. Reagan - New England Journal of Medicine 2020 cited by 1,823

  4. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

    Authors: Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Jeffrey S. Wiezorek, Lynn Navale, Allen Xue, Yizhou Jiang, Adrian Bot, John M. Rossi, Jaeyeon Kim, William Y. Go, Sattva S. Neelapu - The Lancet Oncology 2018 cited by 2,251

  5. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

    Authors: Jay Y. Spiegel, Shabnum Patel, Lori Muffly, Nasheed Hossain, Jean Oak, John H. Baird, Matthew J. Frank, Parveen Shiraz, Bita Sahaf, Juliana Craig, María Iglesias, Sheren Younes, Yasodha Natkunam, Michael G. Ozawa, Eric Yang, John Tamaresis, Harshini Chinnasamy, Zachary Ehlinger, Warren D. Reynolds, Rachel C. Lynn, Maria Caterina Rotiroti, Nikolaos Gkitsas, Sally Arai, Laura Johnston, Robert Lowsky, Robbie G. Majzner, Everett Meyer, Robert S. Negrin, Andrew R. Rezvani, Surbhi Sidana, Judith A. Shizuru, Wen‐Kai Weng, Chelsea Mullins, Allison P. Jacob, Ilan Kirsch, Magali Bazzano, Jing Zhou, Sean Mackay, Scott J. Bornheimer, Liora M. Schultz, Sneha Ramakrishna, Kara L. Davis, Katherine A. Kong, Nirali N. Shah, Haiying Qin, Terry J. Fry, Steven A. Feldman, Crystal L. Mackall, David B. Miklos - Nature Medicine 2021 cited by 572

  6. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

    Authors: Loretta J. Nastoupil, Michael D. Jain, Lei Feng, Jay Y. Spiegel, Armin Ghobadi, Yi Lin, Saurabh Dahiya, Matthew A. Lunning, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P. McGuirk, Abhinav Deol, Alison R. Sehgal, André Goy, Brian T. Hill, Khoan Vu, Charalambos Andreadis, Javier Muñoz, Jason R. Westin, Julio C. Chávez, Amanda F. Cashen, N. Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke - Journal of Clinical Oncology 2020 cited by 786

  7. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

    Authors: Jason R. Westin, Olalekan O. Oluwole, Marie José Kersten, David B. Miklos, Miguel‐Angel Perales, Armin Ghobadi, Aaron P. Rapoport, Anna Sureda, Caron A. Jacobson, Umar Farooq, Tom van Meerten, Matthew L. Ulrickson, Mahmoud Elsawy, Lori A. Leslie, Sridhar Chaganti, Michael Dickinson, Kathleen Dorritie, Patrick M. Reagan, Joseph P. McGuirk, Kevin Song, Peter A. Riedell, Monique C. Minnema, Yin Yang, Saran Vardhanabhuti, Simone Filosto, Paul Cheng, Shilpa Shahani, Marco Schupp, Christina To, Frederick L. Locke - New England Journal of Medicine 2023 cited by 410

  8. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

    Authors: Frederick L. Locke, John M. Rossi, Sattva S. Neelapu, Caron A. Jacobson, David B. Miklos, Armin Ghobadi, Olalekan O. Oluwole, Patrick M. Reagan, Lazaros J. Lekakis, Yi Lin, Marika Sherman, Marc Better, William Y. Go, Jeffrey S. Wiezorek, Allen Xue, Adrian Bot - Blood Advances 2020 cited by 455

  9. Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy

    Authors: Zinaida Good, Jay Y. Spiegel, Bita Sahaf, Meena Malipatlolla, Zachary Ehlinger, Sreevidya Kurra, Moksha H. Desai, Warren D. Reynolds, Anita Wong Lin, Panayiotis Vandris, Fang Wu, Snehit Prabhu, Mark Hamilton, John Tamaresis, Paul Hanson, Shabnum Patel, Steven A. Feldman, Matthew J. Frank, John H. Baird, Lori Muffly, Gursharan K. Claire, Juliana Craig, Katherine A. Kong, Dhananjay Wagh, John A. Coller, Sean C. Bendall, Robert Tibshirani, Sylvia K. Plevritis, David B. Miklos, Crystal L. Mackall - Nature Medicine 2022 cited by 244

  10. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

    Authors: Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Adrian A. Bot, Rhine R. Shen, Jinghui Dong, Kanwarjit Singh, Harry Miao, Jaeyeon Kim, Yan Zheng, Frederick L. Locke - Blood 2023 cited by 228

  11. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

    Authors: Michael Wang, Javier Muñoz, André Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Krimo Bouabdallah, Rashmi Khanal, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Patrick M. Reagan - Journal of Clinical Oncology 2022 cited by 318

  12. Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy

    Authors: Mark Hamilton, Takeshi Sugio, Troy Noordenbos, Shuyu Shi, Philip L. Bulterys, Chih Long Liu, Xiaoman Kang, Mari Olsen, Zinaida Good, Saurabh Dahiya, Matthew Frank, Bita Sahaf, Crystal L. Mackall, Dita Gratzinger, Maximilian Diehn, Ash A. Alizadeh, David B. Miklos - New England Journal of Medicine 2024 cited by 187

  13. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States

    Authors: Caron A. Jacobson, Frederick L. Locke, Long Ma, Julius Asubonteng, Zhen‐Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David B. Miklos, Yi Lin, Miguel‐Angel Perales, Matthew A. Lunning, Megan M. Herr, Brian T. Hill, Siddhartha Ganguly, Hua Dong, Sarah Nikiforow, Michele Hooper, Jun Kawashima, Hairong Xu, Marcelo C. Pasquini - Transplantation and Cellular Therapy 2022 cited by 181

  14. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies

    Authors: Daniel A. Winer, Shawn Winer, Lei Shen, Persis P. Wadia, Jason Yantha, Geoffrey Paltser, Hubert Tsui, Ping Wu, Matthew G. Davidson, Michael N. Alonso, H. Xianne Leong, Alec Glassford, Maria Caimol, Justin A. Kenkel, Thomas F. Tedder, Tracey McLaughlin, David B. Miklos, H.‐Michael Dosch, Edgar G. Engleman - Nature Medicine 2011 cited by 1,039

  15. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

    Authors: Nathalie Scholler, Régis Perbost, Frederick L. Locke, Michael D. Jain, Sarah Turcan, Corinne Danan, Edmund C. Chang, Sattva S. Neelapu, David B. Miklos, Caron A. Jacobson, Lazaros J. Lekakis, Yi Lin, Armin Ghobadi, Jaeyeon Kim, Justin Chou, Vicki Plaks, Zixing Wang, Allen Xue, Mike Mattie, John M. Rossi, Adrian Bot, Jérôme Galon - Nature Medicine 2022 cited by 198

  16. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

    Authors: Yucai Wang, Preetesh Jain, Frederick L. Locke, Matthew J. Maurer, Matthew J. Frank, Javier Muñoz, Saurabh Dahiya, Amer Beitinjaneh, Miriam T. Jacobs, Joseph P. McGuirk, Julie M. Vose, André Goy, Charalambos Andreadis, Brian T. Hill, Kathleen Dorritie, Olalekan O. Oluwole, Abhinav Deol, Jonas Paludo, Bijal Shah, Trent Wang, Rahul Banerjee, David B. Miklos, Aaron P. Rapoport, Lazaros J. Lekakis, Armin Ghobadi, Sattva S. Neelapu, Yi Lin, Michael Wang, Michael D. Jain - Journal of Clinical Oncology 2023 cited by 176

  17. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

    Authors: David B. Miklos, Corey Cutler, Mukta Arora, Edmund K. Waller, Madan Jagasia, Iskra Pusic, Mary E.D. Flowers, Aaron C. Logan, Ryotaro Nakamura, Bruce R. Blazar, Yunfeng Li, Stephen Chang, Indu Lal, Jason A. Dubovsky, Danelle F. James, Lori Styles, Samantha Jaglowski - Blood 2017 cited by 499

  18. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

    Authors: Vicki Plaks, John M. Rossi, Justin Chou, Linghua Wang, Soumya Poddar, Guangchun Han, Zixing Wang, Shao-Qing Kuang, Fuliang Chu, R. Eric Davis, Francisco Vega, Zahid Bashir, Caron A. Jacobson, Frederick L. Locke, Patrick M. Reagan, Scott J. Rodig, Lazaros J. Lekakis, Ian W. Flinn, David B. Miklos, Adrian Bot, Sattva S. Neelapu - Blood 2021 cited by 189

  19. Evaluation of advanced oxidation processes for water and wastewater treatment – A critical review

    Authors: David B. Miklos, Christian Remy, Martin Jekel, Karl G. Linden, Jörg E. Drewes, Uwe Hübner - Water Research 2018 cited by 2,947

  20. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma

    Authors: John H. Baird, David J. Epstein, John Tamaresis, Zachary Ehlinger, Jay Y. Spiegel, Juliana Craig, Gursharan K. Claire, Matthew J. Frank, Lori Muffly, Parveen Shiraz, Everett Meyer, Sally Arai, J. Martin Brown, Laura Johnston, Robert Lowsky, Robert S. Negrin, Andrew R. Rezvani, Wen‐Kai Weng, Theresa Latchford, Bita Sahaf, Crystal L. Mackall, David B. Miklos, Surbhi Sidana - Blood Advances 2021 cited by 193

  21. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas

    Authors: Brian J. Sworder, David M. Kurtz, Stefan Alig, Matthew J. Frank, Navika Shukla, Andrea Garofalo, Charles Macaulay, Mohammad Shahrokh Esfahani, Mari Olsen, James N. Hamilton, Hitomi Hosoya, Mark Hamilton, Jay Y. Spiegel, John H. Baird, Takeshi Sugio, Mia Carleton, Alexander Craig, Sheren Younes, Bita Sahaf, Natasha Sheybani, Joseph G. Schroers‐Martin, Chih Long Liu, Jean Oak, Michael C. Jin, Sara Beygi, Andreas Hüttmann, Christine Hanoun, Ulrich Dührsen, Jason R. Westin, Michael S. Khodadoust, Yasodha Natkunam, Robbie G. Majzner, Crystal L. Mackall, Maximilian Diehn, David B. Miklos, Ash A. Alizadeh - Cancer Cell 2022 cited by 133

  22. Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial

    Authors: Matthew J. Frank, Nasheed Hossain, Ali Bukhari, Erin Dean, Jay Y. Spiegel, Gursharan K. Claire, Ilan Kirsch, Allison P. Jacob, Chelsea Mullins, Lik Wee Lee, Katherine A. Kong, Juliana Craig, Crystal L. Mackall, Aaron P. Rapoport, Michael D. Jain, Saurabh Dahiya, Frederick L. Locke, David B. Miklos - Journal of Clinical Oncology 2021 cited by 151

  23. Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

    Authors: Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Lazaros J. Lekakis, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick M. Reagan, Adrian Bot, John M. Rossi, Marika Sherman, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeffrey S. Wiezorek, William Y. Go, David B. Miklos - Blood 2017 cited by 181

  24. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease

    Authors: Kenneth R. Cooke, Leo Luznik, Stefanie Sarantopoulos, Frances T. Hakim, Madan Jagasia, Daniel H. Fowler, Marcel R.M. van den Brink, John A. Hansen, Robertson Parkman, David B. Miklos, Paul J. Martin, Sophie Paczesny, Georgia B. Vogelsang, Steven Z. Pavletic, Jerome Ritz, Kirk R. Schultz, Bruce R. Blazar - Biology of Blood and Marrow Transplantation 2016 cited by 456